RedHill Biopharma Announced Positive Recommendation from Independent Committee to Continue U.S. Phase 2 COVID-19 Study, and Approval of COVID-19 Phase 2/3 Study in Italy
| | |

RedHill Biopharma Announced Positive Recommendation from Independent Committee to Continue U.S. Phase 2 COVID-19 Study, and Approval of COVID-19 Phase 2/3 Study in Italy

On Aug. 27, 2020, RedHill Biopharma announced that its U.S. Phase 2 study with opaganib (Yeliva®, ABC294640) in…

Assembly Biosciences and Arbutus announced collaboration to evaluate combination of core inhibitor ABI-H0731 with RNAi Therapeutic AB-729 in patients with Chronic Hepatitis B Virus Infection
| | |

Assembly Biosciences and Arbutus announced collaboration to evaluate combination of core inhibitor ABI-H0731 with RNAi Therapeutic AB-729 in patients with Chronic Hepatitis B Virus Infection

On Aug. 27, 2020, Assembly Biosciences and Arbutus Biopharma announced that the companies have entered into a clinical…